Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections
Abstract
(CRE) are included in the list of the most threatening antibiotic resistance microorganisms, being responsible for often insurmountable therapeutic issues, especially in hospitalized patients and immunocompromised individuals and patients in intensive care units. The enzymatic resistance to carbapenems is encoded by different β-lactamases belonging to A, B or D Ambler class. Besides compromising the activity of last-resort antibiotics, CRE have spread from the clinical to the environmental sectors, in all geographic regions. The purpose of this review is to present present and future perspectives on CRE-associated infections treatment.
Read the paper
Related studies
- Mechanisms of Antibiotic Resistance in Important Gram-Positive and Gram-Negative Pathogens and Novel Antibiotic Solutions
- Clinical challenges treatingStenotrophomonas maltophiliainfections: an update
- Guidelines on Implementing Antimicrobial Stewardship Programs in Korea
- Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies
- What’s old is new again: Insights into diabetic foot microbiome
- Multidrug resistant (or antimicrobial-resistant) pathogens - alternatives to new antibiotics?
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.